ROIV
NASDAQ · Biotechnology
Roivant Sciences Ltd
$40.92
+0.25 (+0.61%)
ROIV News2 articles
Roivant Dips 2.7% Despite FDA Nod for LISRAYA; JPMorgan Sees $2B Peak Sales
Roivant shares slipped 2.7% to $36.58 despite FDA approval of LISRAYA, the first oral treatment for dermatomyositis. JPMorgan sees peak U.S. sales exceeding $2 billion.
Immunovant Shares Surge on Promising Arthritis Drug Data
Immunovant shares soared 35% after its experimental rheumatoid arthritis drug, IMVT-1402, demonstrated high response rates in a difficult-to-treat patient population, prompting a re-rating by Wall Street.